China Specifies Targets of Sweeping Anti-Graft Probe Into Medical, Drug Sectors

Authorities have specified the direction of a recently launched year-long anti-graft probe into China’s medical and pharmaceutical sectors, with rent-seeking, kickbacks and other forms of bribery, as well as misuse of health insurance funds particular areas of focus.

The crackdown is targeting six areas, the National Health Commission (NHC) said in a statement Tuesday. They include rent-seeking by health administrators; bribery in service providers run by health administrators; illegal drug trading by pharmaceutical companies; kickbacks in medical institutions and the sale of drugs, medical devices and consumables; misuse of health insurance funds; and integrity breaches by medical personnel.